PROF
Research Snapshot
Static fundamentals, valuation context, and investor signals for Profound Medical Corp. (PROF).
DCF ready
Valuation
N/A
EV/FCF, N/A FCF yield
Quality
-60.0%
ROIC, -238.4% FCF margin
Growth
N/A
5Y sales (revenue) CAGR
Balance sheet
0.1x
Debt/equity, 12.5x current ratio
Superinvestors
1
Top: First Eagle Investment Management (0.0%)
Strengths to research
- Debt/equity looks manageable at 0.1x.
Watchouts
- Free cash flow margin is negative at -238.4%.
- Valuation multiples are limited or unavailable.
Annual data: 3 periods
Quarterly data: 8 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for PROF.
Grade F
2
/ 100
Financial Charts
No financial data available for PROF (annual).
1 superinvestors own PROF
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| First Eagle Investment Management First Eagle Investment Management | 322,707 | $2M | 0.00% | 0.0% |